373 related articles for article (PubMed ID: 19133120)
41. Ursodeoxycholic acid shows antineoplastic effects in bile duct cancer cells via apoptosis induction; p53 activation; and EGFR-ERK, COX-2, and PI3K-AKT pathway inhibition.
Lee J; Hong EM; Kim JH; Kim JH; Jung JH; Park SW; Koh DH; Jang HJ
Mol Biol Rep; 2021 Sep; 48(9):6231-6240. PubMed ID: 34392440
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
43. Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways.
Hagemeister AL; Sheridan MA
Am J Physiol Regul Integr Comp Physiol; 2008 Aug; 295(2):R490-7. PubMed ID: 18495839
[TBL] [Abstract][Full Text] [Related]
44. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
Bhowmik T; Gomes A
Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
[TBL] [Abstract][Full Text] [Related]
45. Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2.
Sako K; Fukuhara S; Minami T; Hamakubo T; Song H; Kodama T; Fukamizu A; Gutkind JS; Koh GY; Mochizuki N
J Biol Chem; 2009 Feb; 284(9):5592-601. PubMed ID: 19106103
[TBL] [Abstract][Full Text] [Related]
46. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
[TBL] [Abstract][Full Text] [Related]
47. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
Dillon LM; Bean JR; Yang W; Shee K; Symonds LK; Balko JM; McDonald WH; Liu S; Gonzalez-Angulo AM; Mills GB; Arteaga CL; Miller TW
Oncogene; 2015 Jul; 34(30):3968-76. PubMed ID: 25284585
[TBL] [Abstract][Full Text] [Related]
48. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
[TBL] [Abstract][Full Text] [Related]
49. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
50. Novel ferrocenyl pyrazoles inhibit breast cancer cell viability via induction of apoptosis and inhibition of PI3K/Akt and ERK1/2 signaling.
Atmaca H; Özkan AN; Zora M
Chem Biol Interact; 2017 Feb; 263():28-35. PubMed ID: 27989600
[TBL] [Abstract][Full Text] [Related]
51. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
[TBL] [Abstract][Full Text] [Related]
52. ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation.
Meng X; Hu B; Hossain MM; Chen G; Sun Y; Zhang X
Int J Oncol; 2016 Aug; 49(2):682-90. PubMed ID: 27221510
[TBL] [Abstract][Full Text] [Related]
53. Insulin-like growth factor 1 inhibits extracellular signal-regulated kinase to promote neuronal survival via the phosphatidylinositol 3-kinase/protein kinase A/c-Raf pathway.
Subramaniam S; Shahani N; Strelau J; Laliberté C; Brandt R; Kaplan D; Unsicker K
J Neurosci; 2005 Mar; 25(11):2838-52. PubMed ID: 15772344
[TBL] [Abstract][Full Text] [Related]
54. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
55. Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation.
Worthington J; Bertani M; Chan HL; Gerrits B; Timms JF
BMC Cancer; 2010 Sep; 10():490. PubMed ID: 20840765
[TBL] [Abstract][Full Text] [Related]
56. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
57. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
58. c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.
Tang MK; Zhou HY; Yam JW; Wong AS
Neoplasia; 2010 Feb; 12(2):128-38. PubMed ID: 20126471
[TBL] [Abstract][Full Text] [Related]
59. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of α-enolase affects the biological activity of breast cancer cells by attenuating PI3K/Akt signaling pathway.
Zang HY; Gong LG; Li SY; Hao JG
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):249-257. PubMed ID: 31957838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
